These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

157 related articles for article (PubMed ID: 25686112)

  • 1. Targeting triple-negative breast cancer and high-grade ovarian carcinoma: refining BRCAness beyond BRCA1/2 mutations?
    Jacot W; Theillet C; Guiu S; Lamy PJ
    Future Oncol; 2015; 11(4):557-9. PubMed ID: 25686112
    [No Abstract]   [Full Text] [Related]  

  • 2. [Role of oncogenetics in the treatment of breast and ovarian cancer].
    Langmár Z; Németh M
    Orv Hetil; 2011 Jul; 152(30):1214-5. PubMed ID: 21733796
    [No Abstract]   [Full Text] [Related]  

  • 3. Olaparib in patients with recurrent high-grade serous or poorly differentiated ovarian carcinoma or triple-negative breast cancer: a phase 2, multicentre, open-label, non-randomised study.
    Gelmon KA; Tischkowitz M; Mackay H; Swenerton K; Robidoux A; Tonkin K; Hirte H; Huntsman D; Clemons M; Gilks B; Yerushalmi R; Macpherson E; Carmichael J; Oza A
    Lancet Oncol; 2011 Sep; 12(9):852-61. PubMed ID: 21862407
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Prevalence of BRCA1 and BRCA2 germline mutations in patients with triple-negative breast cancer.
    Wong-Brown MW; Meldrum CJ; Carpenter JE; Clarke CL; Narod SA; Jakubowska A; Rudnicka H; Lubinski J; Scott RJ
    Breast Cancer Res Treat; 2015 Feb; 150(1):71-80. PubMed ID: 25682074
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Olaparib in ovarian cancer with BRCA mutation].
    Pujade-Lauraine É; Combe P
    Bull Cancer; 2015 Jun; 102(6 Suppl 1):S82-4. PubMed ID: 26118881
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Oral poly(ADP-ribose) polymerase inhibitor olaparib in patients with BRCA1 or BRCA2 mutations and recurrent ovarian cancer: a proof-of-concept trial.
    Audeh MW; Carmichael J; Penson RT; Friedlander M; Powell B; Bell-McGuinn KM; Scott C; Weitzel JN; Oaknin A; Loman N; Lu K; Schmutzler RK; Matulonis U; Wickens M; Tutt A
    Lancet; 2010 Jul; 376(9737):245-51. PubMed ID: 20609468
    [TBL] [Abstract][Full Text] [Related]  

  • 7. BRCA1/2-negative hereditary triple-negative breast cancers exhibit BRCAness.
    Domagala P; Hybiak J; Cybulski C; Lubinski J
    Int J Cancer; 2017 Apr; 140(7):1545-1550. PubMed ID: 27943282
    [TBL] [Abstract][Full Text] [Related]  

  • 8. PARP inhibition: targeting the Achilles' heel of DNA repair to treat germline and sporadic ovarian cancers.
    Carden CP; Yap TA; Kaye SB
    Curr Opin Oncol; 2010 Sep; 22(5):473-80. PubMed ID: 20485165
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A multi-institutional study on the association between BRCA1/BRCA2 mutational status and triple-negative breast cancer in familial breast cancer patients.
    Seong MW; Kim KH; Chung IY; Kang E; Lee JW; Park SK; Lee MH; Lee JE; Noh DY; Son BH; Park HL; Cho SI; Park SS; ; Kim SW
    Breast Cancer Res Treat; 2014 Jul; 146(1):63-9. PubMed ID: 24894343
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Hereditary ovarian carcinomas: clinico-biological features and treatment].
    Floquet A; Stoeckle E; Croce S; Longy M; Mc Grogan G; Barouk E; Bubien V; Garbay D; Joly E; Guyon F
    Bull Cancer; 2014 Feb; 101(2):167-74. PubMed ID: 24555961
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Nonequivalent gene expression and copy number alterations in high-grade serous ovarian cancers with BRCA1 and BRCA2 mutations.
    George J; Alsop K; Etemadmoghadam D; Hondow H; Mikeska T; Dobrovic A; deFazio A; ; Smyth GK; Levine DA; Mitchell G; Bowtell DD
    Clin Cancer Res; 2013 Jul; 19(13):3474-84. PubMed ID: 23633455
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Screening for common mutations in BRCA1 and BRCA2 genes: interest in genetic testing of Tunisian families with breast and/or ovarian cancer.
    Fourati A; Louchez MM; Fournier J; Gamoudi A; Rahal K; El May MV; El May A; Revillion F; Peyrat JP
    Bull Cancer; 2014 Nov; 101(11):E36-40. PubMed ID: 25418591
    [TBL] [Abstract][Full Text] [Related]  

  • 13. PARP inhibition in BRCA-mutated breast and ovarian cancers.
    Chan SL; Mok T
    Lancet; 2010 Jul; 376(9737):211-3. PubMed ID: 20656109
    [No Abstract]   [Full Text] [Related]  

  • 14. The role of poly adenosine diphosphate ribose polymerase inhibitors in breast and ovarian cancer: current status and future directions.
    Chionh F; Mitchell G; Lindeman GJ; Friedlander M; Scott CL
    Asia Pac J Clin Oncol; 2011 Sep; 7(3):197-211. PubMed ID: 21884432
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Therapeutic potential of poly(ADP-ribose) polymerase inhibitor AG014699 in human cancers with mutated or methylated BRCA1 or BRCA2.
    Drew Y; Mulligan EA; Vong WT; Thomas HD; Kahn S; Kyle S; Mukhopadhyay A; Los G; Hostomsky Z; Plummer ER; Edmondson RJ; Curtin NJ
    J Natl Cancer Inst; 2011 Feb; 103(4):334-46. PubMed ID: 21183737
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [PARP inhibitors: new therapeutic agents in breast and ovarian cancer].
    Mercier-Vogel L; Bodmer A; Castiglione M
    Rev Med Suisse; 2011 May; 7(296):1137-40. PubMed ID: 21721203
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Personalizing therapy for ovarian cancer: BRCAness and beyond.
    Bast RC; Mills GB
    J Clin Oncol; 2010 Aug; 28(22):3545-8. PubMed ID: 20547987
    [No Abstract]   [Full Text] [Related]  

  • 18. PARP inhibitors: targeting the right patients.
    Azvolinsky A
    J Natl Cancer Inst; 2012 Dec; 104(24):1851-2. PubMed ID: 23231976
    [No Abstract]   [Full Text] [Related]  

  • 19. Olaparib combined with chemotherapy for recurrent platinum-sensitive ovarian cancer: a randomised phase 2 trial.
    Oza AM; Cibula D; Benzaquen AO; Poole C; Mathijssen RH; Sonke GS; Colombo N; Špaček J; Vuylsteke P; Hirte H; Mahner S; Plante M; Schmalfeldt B; Mackay H; Rowbottom J; Lowe ES; Dougherty B; Barrett JC; Friedlander M
    Lancet Oncol; 2015 Jan; 16(1):87-97. PubMed ID: 25481791
    [TBL] [Abstract][Full Text] [Related]  

  • 20. BRCAness predicts resistance to taxane-containing regimens in triple negative breast cancer during neoadjuvant chemotherapy.
    Akashi-Tanaka S; Watanabe C; Takamaru T; Kuwayama T; Ikeda M; Ohyama H; Mori M; Yoshida R; Hashimoto R; Terumasa S; Enokido K; Hirota Y; Okuyama H; Nakamura S
    Clin Breast Cancer; 2015 Feb; 15(1):80-5. PubMed ID: 25445419
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.